RFL Rafael Holdings, Inc. Class B Common Stock
XNYS 1.67 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
RFL
$1.67
—
Key stats
$1.67
- 52-Week Range
- $1.12 – $3.96
- YTD
- +32.94%
- Straddle Price
- $1.38
- P/C Vol Ratio
- 0.00
- Market Cap
- $0.1B
- Open
- $1.27
- Day Range
- $1.26 – $1.28
- Volume
- 4,014
- Prev Close
- $1.30
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 0.88 |
| Cost of Equity (CAPM) | 9.54% (VRP-adj) |
| WACC | 9.44% |
| Volatility Risk Premium | +158.5pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -43.2% |
| Book / Price | 135.8% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 95.1% |
| FCF Margin (TTM) | -3264.7% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $1.93 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $1.55 |
| Bollinger Width / SMA20 | 3841.6% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$3.10
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 39.6× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.0× · 3 peers |
| Peer P/B | $6.13 | 50% | median 3.5× · 3 peers |
| Peer P/S | $0.08 | 50% | median 3.8× · 3 peers |
| Market Anchor (SMA50) | $1.93 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNYS
- Market Cap
- $0.1B
- Employees
- 23
- List Date
- 2018-03-06
- CIK
- 0001713863
- Next Earnings
- 2026-11-04 (After-Close)
- Headquarters
- Newark, NJ
- Homepage
- https://www.rafaelholdings.com
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 4.22% | -20.84% | 6.74% | -1.09% | 17.05% | -7.94% | -0.31% |
| Feb | 52.19% | -24.10% | 4.33% | -6.01% | -0.49% | 7.63% | 5.59% |
| Mar | 10.58% | -14.63% | -27.91% | 0.00% | -1.06% | -13.79% | -7.80% |
| Apr | 1.72% | -23.76% | 28.05% | -9.14% | -14.13% | 2.42% | -2.47% |
| May | 21.08% | -9.30% | 0.99% | -5.56% | -10.63% | 10.48% | 1.18% |
| Jun | 0.33% | -1.58% | -4.13% | -8.28% | 17.69% | 135.97% | 23.33% |
| Jul | -6.80% | 1.51% | -6.10% | 1.36% | -12.44% | -48.13% | -11.77% |
| Aug | -15.68% | 12.44% | 7.88% | 0.00% | -16.00% | 28.50% | 2.86% |
| Sep | -26.27% | -18.18% | -13.64% | 30.20% | -1.45% | -45.90% | -12.54% |
| Oct | -76.24% | -3.80% | -7.29% | -5.61% | -2.16% | -16.00%* | -18.52% |
| Nov | -25.81% | 1.55% | 1.14% | 2.73% | -12.59% | -- | -6.60% |
| Dec | -9.25% | -2.09% | 0.00% | -8.84% | -3.28% | -- | -4.69% |
| Total | -79.91% | -68.82% | -18.36% | -14.65% | -37.60% | -30.92% | -41.71% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.52
SMA 50: $1.92
SMA 200: $1.68
Current: $1.26
EMA 12: $1.41
EMA 26: $1.60
MACD: -0.1863 | Signal: -0.0065
BEARISH
ADX (14): 32.44
TREND
+DI: 11.73
−DI: 29.28
Momentum Oscillators
RSI (14): 30.26
NEUTRAL
Stoch %K: 9.29
Stoch %D: 12.57
Williams %R: -92.50
Volume & Volatility
BB Upper: $1.96
BB Lower: $1.07
NEUTRAL
OBV: 4,514,946
Vol SMA 20: 204,478
Vol ROC: -97.30%
ATR: $0.15
True Range: $0.04
HV 20: 170.5%
HV 30: 139.4%
HV 60: 113.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall assessment: NEUTRAL (Confidence level: 6/10)
Key drivers:
- Recent positive news headlines and merger announcements have boosted sentiment
- Strong volume indicators suggest institutional interest
- Momentum oscillators indicate a neutral trend
Primary risks:
- High volatility levels may lead to significant price swings
- Options market pricing suggests a moderate move by expiration, which could impact returns
Investment thesis: RFL's recent performance has been driven by positive news and merger announcements. While the stock appears to be in a consolidation phase, its relatively low beta and stable volume indicators suggest it could be a decent hedge or value play.
Recent news sentiment impact:
- Positive news headlines have contributed to the stock's upward momentum
- Neutral news sentiments have not had a significant impact on price
Technical Analysis
Trend direction: NEUTRAL (short-term), BULLISH (medium-term)
Support/resistance levels:
- Lower band: $1.83
- Middle band: $2.06
- Upper band: $2.28
- SMA 20: $2.06
- SMA 50: $2.27
Momentum signals:
- RSI interpretation: Neutral (46.82)
- MACD signal: Bearish (Histogram -0.09)
- Bollinger Bands position: Neutral (squeeze)
Volume analysis:
- Volume SMA 20: 94016.45
- On-Balance Volume (OBV): 7329683.38
- Volume Rate of Change: 125.46%
News & Sentiment Analysis
Recent headlines summary:
- Positive news headlines have focused on merger announcements and revenue growth
- Neutral news headlines have reported earnings results and general market commentary
- No recent negative news headlines have had a significant impact on price
Sentiment assessment: POSITIVE (based on 2 positive and 4 neutral news headlines)
Catalyst identification:
- Merger announcements and regulatory changes
- Earnings reports and product launches
Market narrative:
- The stock's recent performance has been driven by positive news and merger announcements, which aligns with its bullish medium-term trend
Risk & Volatility Assessment
Risk assessment:
- Beta: 0.83 (relatively low volatility)
- IV rank: 39.3% (medium - shows if volatility is historically high/low)
Volatility regime:
- Current vs historical volatility levels: Moderate (average True Range $0.22)
Options market signals:
- IV premium vs HV30: 176.6% (positive - implies implied richer than realized)
- Put-call volume ratio: 0.18 (Bullish sentiment)
Downside protection:
- Support levels: Lower band ($1.83), Middle band ($2.06)
- Risk management considerations: Stop-loss levels and position sizing considerations
Market Context & Positioning
Sector performance:
- Relative strength vs sector/market: Neutral
Institutional activity:
- Volume patterns suggesting institutional interest: Strong volume indicators (94016.45)
Correlation analysis:
- How stock moves relative to market (R-squared interpretation): 0.14 (moderate correlation)
Relative valuation:
- Position within trading range: Consolidation phase
Key Levels & Action Items
Critical price levels:
- Support/resistance: Lower band ($1.83), Middle band ($2.06), Upper band ($2.28)
- SMA 20: $2.06
- SMA 50: $2.27
Breakout/breakdown levels:
- Technical levels that could trigger significant moves: None identified
Time-sensitive catalysts:
- Earnings dates, FDA approvals, product launches: No upcoming events identified
Risk management:
- Stop-loss levels and position sizing considerations: Based on volatility and risk assessment
Note: This analysis is based on the provided data and does not constitute a buy or sell recommendation.
Generated
News
All RFL news →
The news doesn’t stop when markets close. Hosts David Gura, Christina Ruffini and Lisa Mateo bring clarity, context and a bit of humor to the weekend’s biggest headlines, LIVE from New York. Joined by IAEA Director General Rafael Grossi, The New York Times Finance Reporter…
IAEA Director General Rafael Mariano Grossi sat down with David Gura and said that Iran retains a significant amount of uranium enriched to 60%, while inspectors have lost access needed to verify the status of nuclear material and facilities damaged by military strikes. Grossi…
IAEA Director General Rafael Grossi joins Bloomberg's David Bura at the UNGA to discuss the nuclear situation in Iran. He says there is still a fairly important amount of nuclear material in Iran and that the IAEA can get on the ground and assess pretty fast if there is the…
IAEA Director General Rafael Grossi joins Bloomberg's David Gura at the United Nations General Assembly to discuss the nuclear situation in Iran. He says there is still a fairly important amount of nuclear material in Iran and that the IAEA can get on the ground and assess…
Earnings History
13 of 14 under expected move
Avg Expected Move
95.66%
Avg Actual Move
3.75%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-17 | After-Close | 11.49% | 1.78% | 0.15x | Within |
| 2021-06-14 | After-Close | 3.10% | 7.13% | 2.30x | Exceeded |
| 2021-10-18 | After-Close | 46.08% | 1.63% | 0.04x | Within |
| 2021-12-15 | After-Close | 15.95% | 0.94% | 0.06x | Within |
| 2023-06-13 | After-Close | 24.09% | 2.27% | 0.09x | Within |
| 2023-10-30 | After-Close | 50.00% | 3.49% | 0.07x | Within |
| 2024-03-14 | After-Close | 39.53% | 0.58% | 0.01x | Within |
| 2024-06-14 | After-Close | 433.57% | 3.50% | 0.01x | Within |
| 2024-11-07 | After-Close | 23.68% | 2.63% | 0.11x | Within |
| 2025-03-14 | After-Close | 325.14% | 1.09% | 0.00x | Within |
| 2025-06-11 | After-Close | 35.19% | 6.80% | 0.19x | Within |
| 2025-10-29 | After-Close | 143.66% | 0.75% | 0.01x | Within |
| 2026-03-16 | After-Close | 152.67% | 0.76% | 0.00x | Within |
| 2026-06-10 | After-Close | 35.11% | 19.10% | 0.54x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
RFL Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $1.38
7-DTE Move: $1.38
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 267
Put Volume: 1
P/C Volume: 0.004
BULLISH
Call OI: 5,793
Put OI: 206
P/C OI: 0.036
Total OI: 5,999
ATM Options Pricing
ATM Call: $0.15
ATM Put: $1.23
Call %: 9.0%
Put %: 73.1%
Chain Summary
Chain Volume: 298
Chain OI: 6,797
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 49th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
49%
vs own history
GEX tilt
+0.32
OI-weighted, today
Vanna tilt
+0.36
δ-sensitivity to IV
Charm tilt
-0.67
δ-decay vs time
Vanna tilt +0.36: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.67: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
ATM 326.9% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$1.38Oct 22
Beta Analysis
Risk Metrics
Beta: 0.8062
Alpha: 15.59%
Correlation: 0.1225
R-Squared: 1.5%
Stock Volatility: 83.8%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own RFL
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $196K | #2886 of 3138 | -32.9% | 13F | |
| Citadel Hedge fund Ken Griffin | $161K | #5583 of 6285 | +364.2% | 13F | |
| Point72 Hedge fund Steve Cohen | $34K | #1893 of 1945 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
RFL Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 45,765,574 (as of 2026-04-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
2 filers$475.27K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $343.09K | 72.19% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $132.18K | 27.81% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
RFL Insider Trading (Form 4)
Latest: 2026-09-23Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | David Polinsky | Chief Financial Officer | Tax (F) | −2,027 | $2.02 | -$4.1K | EDGAR |
| 2026-07-31 | Howard S Jonas | Exec Chairman, CEO & President | Award (A) | +54,945 | $2.73 | $150.0K | EDGAR |
| 2026-06-23 | David Polinsky | Chief Financial Officer | Tax (F) | −2,386 | $2.63 | -$6.3K | EDGAR |
| 2026-06-16 | Howard S Jonas | Exec Chairman, CEO & President | Mixed | +134,071 | $1.78 | $229.5K | EDGAR |
| 2026-03-24 | David Polinsky | Chief Financial Officer | Tax (F) | −2,318 | $1.27 | -$3.0K | EDGAR |
| 2026-03-17 | Howard S Jonas | Exec Chairman, CEO & President | Tax (F) | −9,826 | $1.50 | -$14.8K | EDGAR |
| 2026-01-30 | Markus Sieger | Director | Award (A) | +29,528 | $1.27 | $37.5K | EDGAR |
| 2026-01-29 | Michael J Weiss | Director | Award (A) | +39,370 | $1.27 | $50.0K | EDGAR |
| 2026-01-29 | Mark N Stein | Director | Award (A) | +39,370 | $1.27 | $50.0K | EDGAR |
| 2026-01-29 | Alan Grayson | Director | Award (A) | +6,562 | $1.27 | $8.3K | EDGAR |
| 2026-01-15 | David Polinsky | Chief Financial Officer | Mixed | +45,135 | $1.25 | $56.4K | EDGAR |
| 2026-01-15 | Howard S Jonas | Exec Chairman, CEO & President | Award (A) | +75,000 | $1.25 | $93.6K | EDGAR |
| 2025-12-23 | David Polinsky | Chief Financial Officer | Tax (F) | −1,961 | $1.28 | -$2.5K | EDGAR |
| 2025-12-16 | Howard S Jonas | Exec Chairman, CEO & President | Tax (F) | −9,867 | $1.50 | -$14.8K | EDGAR |
| 2025-03-25 | David Polinsky | Chief Financial Officer | Tax (F) | −2,378 | $1.93 | -$4.6K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
RFL Insider Holdings
9 insiders · @ $1.26
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Howard S Jonas | Exec Chairman, CEO & President | 610,850 | $769.7K | $10.84M | 23 | 2026-07-31 |
| 2 | William Conkling | Chief Executive Officer | 537,001 | $676.6K | $0 | 15 | 2025-03-25 |
| 3 | David Polinsky | Chief Financial Officer | 297,084 | $374.3K | $0 | 19 | 2026-09-23 |
| 4 | Markus Sieger | Director | 219,710 | $276.8K | $0 | 1 | 2026-01-30 |
| 5 | Michael J Weiss | Director | 141,861 | $178.7K | $0 | 8 | 2026-01-29 |
| 6 | Stephen M Greenberg | Director | 102,491 | $129.1K | $0 | 7 | 2025-01-08 |
| 7 | Mark N Stein | Director | 50,845 | $64.1K | $0 | 2 | 2026-01-29 |
| 8 | John Goldberg | CHIEF MEDICAL OFFICER | 50,000 | $63.0K | $0 | 2 | 2025-01-15 |
| 9 | Alan Grayson | Director | 6,562 | $8.3K | $0 | 1 | 2026-01-29 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
RFL Board & Officers
As of SEC filings through Sep 23, 2026Directors 7
- Howard S Jonas · since Jan 2, 2018
- Michael J Weiss · since Mar 8, 2018
- Susan Y Bernstein · since Jan 10, 2024
- Mark N Stein · since Aug 5, 2024
- Markus Sieger · since Mar 25, 2025
- N Scott Fine · since Jul 14, 2025
- Alan Grayson · since Oct 23, 2025
Officers 3
- Howard S Jonas · Exec Chairman, CEO & President · listed since Jun 2025
- David Polinsky · Chief Financial Officer · listed since Jun 2024
- Joshua M Fine · Chief Operations Officer · since Aug 4, 2025
10% owners 1
- Howard S Jonas · listed since Jun 2025
Changes in the last 10 years (50)
| Oct 23, 2025 | The company announced the departure of Stephen M Greenberg from the board in an SEC filing |
| Oct 23, 2025 | Alan Grayson became a director |
| Aug 4, 2025 | The company announced the departure of John Goldberg as Chief Medical Officer in an SEC filing |
| Aug 4, 2025 | Joshua M Fine became Chief Operations Officer |
| Jul 14, 2025 | N Scott Fine became a director |
| Jun 9, 2025 | Howard S Jonas listed as Exec Chairman, CEO & President (previously Executive Chairman) in SEC filings |
| Jun 9, 2025 | Howard S Jonas first listed as a 10% owner in an SEC filing |
| Apr 23, 2025 | The company announced the departure of William Conkling as Chief Executive Officer in an SEC filing |
| Mar 25, 2025 | Markus Sieger became a director |
| Aug 5, 2024 | The company announced the departure of Mark Anthony McCamish from the board in an SEC filing |
| Aug 5, 2024 | Mark N Stein became a director |
| Jun 25, 2024 | David Polinsky first listed as Chief Financial Officer in an SEC filing |
| Jan 10, 2024 | Susan Y Bernstein became a director |
| Nov 20, 2023 | John Goldberg became Chief Medical Officer |
| Sep 26, 2023 | David Polinsky reported in an SEC filing no longer being Chief Financial Officer |
| Aug 7, 2023 | The company announced the departure of Boris C Pasche from the board in an SEC filing |
| Jan 30, 2023 | David Polinsky first listed as Chief Financial Officer in an SEC filing |
| Jan 4, 2023 | The company announced the departure of Patrick Fabbio as CFO & President in an SEC filing |
| Jul 7, 2022 | Howard S Jonas listed as Executive Chairman (previously Chief Executive Officer) in SEC filings |
| Jul 6, 2022 | i9 PLUS, LLC became a 10% owner |
| Jun 16, 2022 | Howard S Jonas no longer listed as a 10% owner in SEC filings |
| May 29, 2022 | The company announced the departure of Ameet Mallik from the board in an SEC filing |
| May 24, 2022 | The company announced the departure of Shannon Thyme Klinger from the board in an SEC filing |
| Apr 12, 2022 | Ameet Mallik first listed as a director in an SEC filing |
| Feb 3, 2022 | William Conkling listed as Chief Executive Officer (previously Chief Commercial Officer) in SEC filings |
| Feb 3, 2022 | Patrick Fabbio listed as CFO & President (previously Chief Financial Officer) in SEC filings |
| Nov 21, 2021 | The company announced the departure of Ameet Mallik as Chief Executive Officer in an SEC filing |
| Oct 18, 2021 | Mary Margaret Huizinga became Chief Devel. & Medical Officer |
| Sep 24, 2021 | David Polinsky reported in an SEC filing no longer being Chief Financial Officer |
| Sep 20, 2021 | Ashok D Marin became Chief Legal Officer |
| Sep 13, 2021 | Patrick Fabbio became Chief Financial Officer |
| Jun 14, 2021 | Shannon Thyme Klinger became a director |
| Jun 14, 2021 | Mark Anthony McCamish became a director |
| May 1, 2021 | Ameet Mallik became Chief Executive Officer |
| Mar 15, 2021 | William Conkling became Chief Commercial Officer |
| Jan 13, 2021 | Rachel Jonas became a director |
| Mar 29, 2018 | Menachem Ash no longer listed as a director in SEC filings |
| Mar 29, 2018 | Joyce J Mason reported in an SEC filing no longer being a director |
| Mar 28, 2018 | Idt Corp reported in an SEC filing no longer being a 10% owner |
| Mar 28, 2018 | Howard S Jonas first listed as a 10% owner in an SEC filing |
| Mar 28, 2018 | Howard S Jonas first listed as Chief Executive Officer in an SEC filing |
| Mar 8, 2018 | Stephen M Greenberg became a director |
| Mar 8, 2018 | Michael J Weiss became a director |
| Mar 8, 2018 | Boris C Pasche became a director |
| Jan 2, 2018 | Menachem Ash became a director |
| Jan 2, 2018 | Menachem Ash became President |
| Jan 2, 2018 | Joyce J Mason became a director |
| Jan 2, 2018 | Howard S Jonas became a director |
| Jan 2, 2018 | David Polinsky became Chief Financial Officer |
| Jan 2, 2017 | Idt Corp became a 10% owner |
Not reported recently (5)
- Rachel Jonas · Last reported as a director in an SEC filing dated Jan 23, 2023
- i9 PLUS, LLC · Last reported as a 10% owner in an SEC filing dated Aug 9, 2022
- Mary Margaret Huizinga · Last reported as Chief Devel. & Medical Officer in an SEC filing dated Oct 19, 2021
- Ashok D Marin · Last reported as Chief Legal Officer in an SEC filing dated Sep 28, 2021
- Menachem Ash · Last reported as President in an SEC filing dated Jan 7, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
10 ETFs hold RFL
10 shown · $2.16M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $1.3M | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $441,086 | — | 2026-09-30 |
| 3 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.01% | $130,133 | $1.2B | 2026-10-20 |
| 4 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.00% | $119,597 | — | 2026-10-20 |
| 5 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $57,752 | — | 2026-10-20 |
| 6 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $47,010 | — | 2026-10-20 |
| 7 | DXUV Dimensional US Vector Equity ETF | Dimensional | 0.00% | $30,907 | — | 2026-10-20 |
| 8 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $25,409 | — | 2026-10-20 |
| 9 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.00% | $14,177 | $3.1B | 2026-10-20 |
| 10 | DFUS Dimensional US Equity Market ETF | Dimensional | 0.00% | $1,189 | $21.4B | 2026-10-20 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.71
TTM Revenue
$980.00K
TTM Net Income
$-32.55M
TTM Op. Cash Flow
$-31.99M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-04-30 | $179.00K | $-4.23M | $-0.08 | $-7.28M |
| Q2 '26 | 2026-01-31 | $211.00K | $-6.42M | $-0.13 | $-7.52M |
| Q1 '26 | 2025-10-31 | $240.00K | $-9.82M | $-0.19 | $-6.81M |
| Q4 '25 | 2025-07-31 | $350.00K | $-12.09M | $-0.31 | $-10.38M |
| Q3 '25 | 2025-04-30 | $362.00K | $-4.78M | $-0.19 | $-3.19M |
| Q2 '25 | 2025-01-31 | $77.00K | $-4.64M | $-0.19 | $-2.31M |
| Q1 '25 | 2024-10-31 | $128.00K | $-9.01M | $-0.37 | $-3.04M |
| Q4 '24 | 2024-07-31 | $165.00K | $-4.47M | $-0.19 | $-2.89M |
| Q3 '24 | 2024-04-30 | $336.00K | $-32.35M | $-1.36 | $-251.00K |
| Q2 '24 | 2024-01-31 | $68.00K | $6.05M | $0.25 | $-2.53M |
| Q1 '24 | 2023-10-31 | $68.00K | $-3.64M | $-0.15 | $-2.13M |
| Q4 '23 | 2023-07-31 | $68.00K | $1.22M | $0.06 | $-1.45M |
Q3 2026 • period ending 2026-04-30 • filed 2026-06-11
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.71
P/S
58.84
EV/EBITDA
—
EV/Sales
27.72
ROE
-40.3%
ROA
-35.4%
Div Yield
0.00%
FCF Yield
-55.48%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$57.66M
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
789.11K
SI % of Float
2.31%
Days to Cover
2.29
Short Vol Ratio
73.1%
Free Float
34.21M
Float %
66.8%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-09-22